VANDA PHARMACEUTICALS INC. Finite-Lived Intangible Asset, Expected Amortization, after Year Five
VANDA PHARMACEUTICALS INC. (VNDA) had Finite-Lived Intangible Asset, Expected Amortization, after Year Five of $77.35 million as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive · last filed 2026-02-12
- 2025-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $77.35M.
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $79.06M.
- 2023-12-31: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $70.35M.
- 2016-09-30: Finite-Lived Intangible Asset, Expected Amortization, after Year Five $20.93M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, after Year Five |
|---|---|
| 2025-12-31 | $77.35M 10-K · filed 2026-02-12 |
| 2024-12-31 | $79.06M 10-K · filed 2025-02-14 |
| 2023-12-31 | $70.35M 10-K · filed 2024-02-08 |
| 2016-09-30 | $20.93M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $20.93M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $20.93M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $20.93M 10-K · filed 2016-02-12 |
| 2015-09-30 | $22.66M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $22.66M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $22.66M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $5.41M 10-K · filed 2015-03-13 |
| 2014-09-30 | $5.82M 10-Q · filed 2014-10-27 |
| 2014-06-30 | $5.82M 10-Q · filed 2014-08-08 |
| 2014-03-31 | $3.59M 10-Q · filed 2014-05-08 |
| 2012-12-31 | $552.00K 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |